RxDoctor Payments Data

Mark Zimmerman, MD

Psychiatry · Cranston, RINPI 1508842857

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (39.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) at 49.3% of the total. Among psychiatry clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$225,125in general payments, 2019–2025

Across 237 payments — averaging $949.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$111K
  • Otsuka Pharmaceutical Co., Ltd.$26K
  • Amgen$20K
  • Merck$20K
  • Johnson & Johnson$9K
  • Boehringer Ingelheim$9K
  • plus $30K from 12 others
$147,310in research payments, 2019–2025

Across 1 payment — averaging $147,310 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boehringer Ingelheim International GmbH$147K

What the payments were for

  • Consulting fees$89,62740%
  • Speaking & faculty fees$79,53335%
  • Travel & lodging$50,74223%
  • Food & beverage$5,2232%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$225,125 in reported general payments places this provider in the 95th percentile of 209 psychiatry providers in Rhode Island.

See all psychiatry providers in Rhode Island

Medicare billing

Part B allowed, 2024
$11,836
Medicare patients
20
Services billed
138

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Bupropion XlBupropion Hcl41$1,599
Duloxetine Hcl40$1,020
Venlafaxine Hcl ErVenlafaxine Hcl22$822
Bupropion Hcl SrBupropion Hcl24$758
Quetiapine Fumarate14$475
Methylphenidate Hcl16$409
Clonazepam67$372
Sertraline Hcl19$322
Lorazepam27$267
Aripiprazole17$198
Citalopram HbrCitalopram Hydrobromide23$135
Trazodone Hcl11$115
Diazepam20$108
Risperidone16$105

Paid to pharmacies, not to this prescriber.

Other psychiatry in Cranston

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →